Matthew Biegler Analyst Performance

Analyst at Oppenheimer

Matthew Biegler is a stock analyst at Oppenheimer in the medical sector, covering 16 publicly traded companies. Over the past year, Matthew Biegler has issued 14 stock ratings, including and buy recommendations. While full access to Matthew Biegler's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Matthew Biegler's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Analyst Ranking

Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat

Average Return

00.00% 12-Month ROI

Success Rate

00.00% Profitable Ratings

Total Ratings

32 Last 5 Years

Buy Recommendations

93.55% 29 Buy Ratings

Companies Covered

16 Unique Companies

Ratings Distribution

Rating	Percentage	Count
Strong Buy	0.0%	0 ratings
Buy	93.5%	29 ratings
Hold	6.5%	2 ratings
Sell	0.0%	0 ratings

Out of 31 total stock ratings issued by Matthew Biegler at Oppenheimer, the majority (93.5%) have been Buy recommendations, followed by 6.5% Hold.

Best & Worst Calls

• Best Call

  0000.0%

  FATE

  Apr 2020

  Subscribe to MarketBeat All Access to get analyst recommendation ROI.
• Worst Call

  000.0%

  PRTG

  Nov 2022

  Subscribe to MarketBeat All Access to get analyst recommendation ROI.

Exchange Coverage

Exchange	Percentage	Count
NASDAQ	93.8% of companies on NASDAQ	15 companies
NYSE	6.3% of companies on NYSE	1 company

Matthew Biegler, an analyst at Oppenheimer, currently covers 16 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector Icon	Sector	Percentage
	Medical 16 companies	100.0%

Matthew Biegler of Oppenheimer specializes in stock coverage within the Medical sector.

Coverage Industries

Industry	Percentage
MED - BIOMED/GENE 10 companies	62.5%
MED - DRUGS 2 companies	12.5%
PHARMACEUTICAL PREPARATIONS 2 companies	12.5%
BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES 1 company	6.3%
BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC 1 company	6.3%

About Matthew Biegler

Matt Biegler is a Senior Analyst covering Emerging Biotechnology. Prior to joining Oppenheimer, Matt worked with Mark Breidenbach covering Biotechnology. Prior to his Wall Street career, Matt spent over five years in the healthcare industry, most recently as a Consultant at Parexel International, a Contract Research Organization. His areas of expertise include clinical trial design and strategy. Matt holds a Bachelor’s degree in Biochemistry and Molecular Biology from Boston University, and a Master’s in Biotechnology from the Columbia University Graduate School of Arts and Sciences.

Follow on LinkedIn

Matthew Biegler's Ratings History at Oppenheimer

Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe

Start Date

End Date

All Ratings Strong Buy Buy Hold Sell Rating

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription

12-Month ROIUpgrade to All Access to use the All ROI Filter

Export to Excel

Company	Report Date	Action	Report Date Price	12-Month Price Target	Rating	12-Month Price & ROI	Details
TYRA Tyra Biosciences	9/10/2025	Reiterated Rating	$11.82	$36.00	Outperform	$0.00 00.00% ROI
IDYA IDEAYA Biosciences	9/8/2025	Set Price Target	$24.98	$36.00	Outperform	$0.00 00.00% ROI
OLMA Olema Pharmaceuticals	9/3/2025	Reiterated Rating	$6.23	$22.00	Outperform	$0.00 00.00% ROI
ACRV Acrivon Therapeutics	8/14/2025	Lower Price Target	$1.29	$8.00	Outperform	$0.00 00.00% ROI
CTMX CytomX Therapeutics	7/31/2025	Initiated Coverage	$2.32	$7.00	Outperform	$0.00 00.00% ROI
NRIX Nurix Therapeutics	7/31/2025	Reiterated Rating	$11.88	$30.00	Outperform	$0.00 00.00% ROI
NRIX Nurix Therapeutics	7/10/2025	Lower Price Target	$12.85	$30.00	Outperform	$0.00 00.00% ROI
ACRV Acrivon Therapeutics	5/15/2025	Lower Price Target	$1.14	$9.00	Outperform	$0.00 00.00% ROI
ALLO Allogene Therapeutics	5/14/2025	Lower Price Target	$0.90	$9.00	Outperform	$0.00 00.00% ROI
OLMA Olema Pharmaceuticals	5/14/2025	Lower Price Target	$4.43	$22.00	Outperform	$0.00 00.00% ROI
ORIC Oric Pharmaceuticals	5/6/2025	Lower Price Target	$5.70	$12.00	Outperform	$0.00 00.00% ROI
VOR Vor Biopharma	3/21/2025	Reiterated Rating	$0.86	$8.00	Outperform	$0.00 00.00% ROI
OLMA Olema Pharmaceuticals	3/19/2025	Reiterated Rating	$4.18	$25.00	Outperform	$0.00 00.00% ROI
ARVN Arvinas	2/12/2025	Boost Price Target	$17.91	$45.00	Outperform	$0.00 00.00% ROI

Stock Forecasts and Research Tools

Sign in to your free account to enjoy these benefits

• In-depth profiles and analysis for 20,000 public companies.
• Real-time analyst ratings, insider transactions, earnings data, and more.
• Our daily ratings and market update email newsletter.

Sign in to your free account to enjoy all that MarketBeat has to offer.

• Sign In
• Create Account

Your Email Address:

Email Address Required

Your Password:

Password Required

Log In

---

or

Sign in with Facebook Sign in with Google

Forgot your password?

Your Email Address:

Please enter your email address.

Please enter a valid email address

Choose a Password:

Please enter your password.

Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character.

Create My Account (Free)

---

or

Sign in with Facebook Sign in with Google

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.